These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. [Antibody treatment for cancer]. Sasaki S; Ozeki I; Takekawa M; Tsujisaki M; Imai K Nihon Geka Gakkai Zasshi; 2000 Sep; 101(9):607-11. PubMed ID: 11022675 [TBL] [Abstract][Full Text] [Related]
24. Therapeutic antibodies--delivering the promise? Hale G Adv Drug Deliv Rev; 2006 Aug; 58(5-6):633-9. PubMed ID: 16822575 [TBL] [Abstract][Full Text] [Related]
25. Antibodies for targeted cancer therapy -- technical aspects and clinical perspectives. Zangemeister-Wittke U Pathobiology; 2005; 72(6):279-86. PubMed ID: 16582579 [TBL] [Abstract][Full Text] [Related]
26. Recombinant immunotoxins and retargeted killer cells: employing engineered antibody fragments for tumor-specific targeting of cytotoxic effectors. Wels W; Biburger M; Müller T; Dälken B; Giesübel U; Tonn T; Uherek C Cancer Immunol Immunother; 2004 Mar; 53(3):217-26. PubMed ID: 14704833 [TBL] [Abstract][Full Text] [Related]
27. A human-mouse chimeric Lym-1 monoclonal antibody with specificity for human lymphomas expressed in a baculovirus system. Hu P; Glasky MS; Yun A; Alauddin MM; Hornick JL; Khawli LA; Epstein AL Hum Antibodies Hybridomas; 1995; 6(2):57-67. PubMed ID: 7492752 [TBL] [Abstract][Full Text] [Related]
28. [Development of antibody drugs targeting against HER2 for cancer therapy]. Tang Q; Ding Q; Lin L; Zhang ZZ; Dai Z; Zhan JB Yao Xue Xue Bao; 2012 Oct; 47(10):1297-305. PubMed ID: 23289141 [TBL] [Abstract][Full Text] [Related]
29. Engineering antibodies for therapy. Adair JR Immunol Rev; 1992 Dec; 130():5-40. PubMed ID: 1286872 [TBL] [Abstract][Full Text] [Related]
30. Elimination of established murine colon carcinoma metastases by antibody-interleukin 2 fusion protein therapy. Xiang R; Lode HN; Dolman CS; Dreier T; Varki NM; Qian X; Lo KM; Lan Y; Super M; Gillies SD; Reisfeld RA Cancer Res; 1997 Nov; 57(21):4948-55. PubMed ID: 9354462 [TBL] [Abstract][Full Text] [Related]
31. New approaches to antibody therapy. Weiner LM; Adams GP Oncogene; 2000 Dec; 19(53):6144-51. PubMed ID: 11156528 [TBL] [Abstract][Full Text] [Related]
32. Recombinant antibody fragments and immunotoxin fusions for cancer therapy. Brinkmann U In Vivo; 2000; 14(1):21-7. PubMed ID: 10757057 [TBL] [Abstract][Full Text] [Related]
33. A mechanistic perspective of monoclonal antibodies in cancer therapy beyond target-related effects. Strome SE; Sausville EA; Mann D Oncologist; 2007 Sep; 12(9):1084-95. PubMed ID: 17914078 [TBL] [Abstract][Full Text] [Related]
34. Advances in monoclonal antibody therapy of cancer. LoBuglio AF; Saleh MN Am J Med Sci; 1992 Sep; 304(3):214-24. PubMed ID: 1476160 [TBL] [Abstract][Full Text] [Related]
36. Production of recombinant immunotherapeutics for anticancer treatment: the role of bioengineering. Pranchevicius MC; Vieira TR Bioengineered; 2013; 4(5):305-12. PubMed ID: 23644447 [TBL] [Abstract][Full Text] [Related]
37. Engineering antibodies for the clinic. Holliger P; Bohlen H Cancer Metastasis Rev; 1999; 18(4):411-9. PubMed ID: 10855784 [TBL] [Abstract][Full Text] [Related]
38. Induction of an immune network cascade in cancer patients treated with monoclonal antibodies (ab1). II. Is induction of anti-idiotype reactive T cells (T3) of importance for tumor response to mAb therapy? Fagerberg J; Frödin JE; Ragnhammar P; Steinitz M; Wigzell H; Mellstedt H Cancer Immunol Immunother; 1994 Mar; 38(3):149-59. PubMed ID: 8124683 [TBL] [Abstract][Full Text] [Related]
39. [Brief overview on the studies of monoclonal antibody]. Tsukagoshi S Nihon Rinsho; 2002 Mar; 60(3):435-8. PubMed ID: 11904954 [TBL] [Abstract][Full Text] [Related]